Le Lézard
Classified in: Health, Science and technology

Avochato secures sixth year of SOC 2 Type II and HIPAA Compliance


Avochato has achieved SOC 2 Type II and HIPAA compliance for the sixth consecutive year, marking a major milestone in its long-term commitment to secure, reliable business messaging. These certifications validate Avochato's ability to serve regulated industries with enterprise-grade data protection, without compromising the speed or simplicity teams love.

MILL VALLEY, Calif., March 27, 2025 /PRNewswire-PRWeb/ -- Avochato, the business messaging platform built for conversations at scale, today announced it has successfully completed its sixth consecutive year of SOC 2 Type II and HIPAA compliance.

From patient updates to financial services, delivery coordination to customer support, Avochato helps organizations have real-time conversations with customers and staff. These certifications mean any customer, especially in regulated industries, can scale knowing data security is a core priority.

"These certifications reflect Avochato's long-standing commitment to data security, privacy, and operational excellence. They matter not only in industries where compliance is non-negotiable but also for every organization that relies on us," said Alex De Simone, co-founder and CEO of Avochato.

SOC 2 Type II is an independent audit that evaluates a company's controls over time, not just at a single point. Achieving this for six straight years speaks to consistency in how Avochato safeguards systems, data, and customer trust. HIPAA compliance, meanwhile, ensures the platform meets the rigorous requirements for handling protected health information, a critical concern for healthcare organizations and their partners.

From patient updates to financial services, delivery coordination to customer support, Avochato helps businesses have real-time conversations with their customers and staff. These latest certifications mean any customer, especially in regulated industries, can scale with Avochato knowing that security and data integrity are foundational priorities.

Avochato's platform enables two-way communication via SMS, MMS, RCS, phone calls, and live chat?all in real time, all on one dashboard. Whether it's appointment reminders, shipping updates, or client outreach, the platform is designed to help teams communicate clearly, quickly, and securely. The added benefit of these compliance milestones is that companies can adopt or scale Avochato without second-guessing its security posture.

In addition to its compliance achievements, Avochato offers a range of built-in features that help businesses stay secure without slowing down operations. Multi-factor authentication (MFA) ensures that only verified users can access the platform, while role-based access controls allow administrators to define permissions and prevent unnecessary exposure to sensitive information. All data is encrypted both in transit and at rest, and additional safeguards can be implemented to obfuscate sensitive content, including MMS and other media attachments.

These security measures are available to all customers, making it easy for businesses of any size to meet their internal privacy standards and external compliance obligations. Together with its SOC 2 Type II and HIPAA certifications, these features make Avochato a reliable messaging partner for teams that can't afford to compromise on data protection.

Media Contact

Niki Camoro, Avochato, 1 415-549-1361, [email protected], https://www.avochato.com 

SOURCE Avochato


These press releases may also interest you

at 15:15
Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the company's AI-powered, non-invasive Cardiac...

at 14:41
Millions of children are at risk following a devastating 7.7 magnitude earthquake that struck Myanmar on 28 March, compounding an already dire humanitarian situation....

at 14:32
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. In 2024, Akeso achieved key success in antibody therapy research...

at 14:30
Eli Lilly and Company today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart...

at 11:00
Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm transcatheter aortic valve replacement (TAVR) system delivers...

at 10:00
Today, Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established...



News published on and distributed by: